Literature DB >> 32038925

KEYNOTE-042 rolls back programmed cell death ligand 1 threshold for non-small cell lung cancer pembrolizumab monotherapy without new insight into those deriving benefit.

Amy Lauren Cummings1, Edward B Garon1.   

Abstract

Entities:  

Year:  2019        PMID： 32038925      PMCID： PMC6987348          DOI： 10.21037/tlcr.2019.07.06

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  16 in total

Review 1.  Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.

Authors:  Takashi Kohno; Takashi Nakaoku; Koji Tsuta; Katsuya Tsuchihara; Shingo Matsumoto; Kiyotaka Yoh; Koichi Goto
Journal:  Transl Lung Cancer Res       Date:  2015-04

Review 2.  Immunotherapy in the Asiatic population: any differences from Caucasian population?

Authors:  Lunxi Peng; Yi-Long Wu
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

3.  Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

Authors:  Leena Gandhi; Delvys Rodríguez-Abreu; Shirish Gadgeel; Emilio Esteban; Enriqueta Felip; Flávia De Angelis; Manuel Domine; Philip Clingan; Maximilian J Hochmair; Steven F Powell; Susanna Y-S Cheng; Helge G Bischoff; Nir Peled; Francesco Grossi; Ross R Jennens; Martin Reck; Rina Hui; Edward B Garon; Michael Boyer; Belén Rubio-Viqueira; Silvia Novello; Takayasu Kurata; Jhanelle E Gray; John Vida; Ziwen Wei; Jing Yang; Harry Raftopoulos; M Catherine Pietanza; Marina C Garassino
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

4.  Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.

Authors:  Narek Shaverdian; Aaron E Lisberg; Krikor Bornazyan; Darlene Veruttipong; Jonathan W Goldman; Silvia C Formenti; Edward B Garon; Percy Lee
Journal:  Lancet Oncol       Date:  2017-05-24       Impact factor: 41.316

5.  PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.

Authors:  Luis G Paz-Ares; Filippo de Marinis; Mircea Dediu; Michael Thomas; Jean-Louis Pujol; Paolo Bidoli; Olivier Molinier; Tarini Prasad Sahoo; Eckart Laack; Martin Reck; Jesús Corral; Symantha Melemed; William John; Nadia Chouaki; Annamaria H Zimmermann; Carla Visseren-Grul; Cesare Gridelli
Journal:  J Clin Oncol       Date:  2013-07-08       Impact factor: 44.544

6.  A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC.

Authors:  A Lisberg; A Cummings; J W Goldman; K Bornazyan; N Reese; T Wang; P Coluzzi; B Ledezma; M Mendenhall; J Hunt; B Wolf; B Jones; J Madrigal; J Horton; M Spiegel; J Carroll; J Gukasyan; T Williams; L Sauer; C Wells; A Hardy; P Linares; C Lim; L Ma; C Adame; Edward B Garon
Journal:  J Thorac Oncol       Date:  2018-06-01       Impact factor: 15.609

7.  Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer.

Authors:  Yunjian Pan; Difan Zheng; Yuan Li; Xu Cai; Zongli Zheng; Yan Jin; Haichuan Hu; Chao Cheng; Lei Shen; Jian Wang; Hongbin Ji; Yihua Sun; Xiaoyan Zhou; Haiquan Chen
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

8.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Authors:  Alan Sandler; Robert Gray; Michael C Perry; Julie Brahmer; Joan H Schiller; Afshin Dowlati; Rogerio Lilenbaum; David H Johnson
Journal:  N Engl J Med       Date:  2006-12-14       Impact factor: 91.245

9.  Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center.

Authors:  Aaron Lisberg; D Andrew Tucker; Jonathan W Goldman; Brian Wolf; James Carroll; Ariana Hardy; Karolyn Morris; Paulina Linares; Carlos Adame; Marshall L Spiegel; Courtney Wells; Jordan McKenzie; Blanca Ledezma; Melody Mendenhall; Phillip Abarca; Krikor Bornazyan; Jaime Hunt; Nima Moghadam; Natalie Chong; Danielle Nameth; Caitlin Marx; John Madrigal; Sitaram Vangala; Narek Shaverdian; David Elashoff; Edward B Garon
Journal:  Cancer Immunol Res       Date:  2018-01-30       Impact factor: 11.151

10.  Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study.

Authors:  Edward B Garon; Matthew D Hellmann; Naiyer A Rizvi; Enric Carcereny; Natasha B Leighl; Myung-Ju Ahn; Joseph Paul Eder; Ani S Balmanoukian; Charu Aggarwal; Leora Horn; Amita Patnaik; Matthew Gubens; Suresh S Ramalingam; Enriqueta Felip; Jonathan W Goldman; Cathie Scalzo; Erin Jensen; Debra A Kush; Rina Hui
Journal:  J Clin Oncol       Date:  2019-06-02       Impact factor: 44.544
View more
  2 in total

1.  Immunotherapy beyond progression in patients with advanced non-small cell lung cancer.

Authors:  Xiangwei Ge; Zhibo Zhang; Sujie Zhang; Fang Yuan; Fan Zhang; Xiang Yan; Xiao Han; Junxun Ma; Lijie Wang; Haitao Tao; Xiaoyan Li; Xiaoyu Zhi; Zhiyue Huang; Paul Hofman; Arsela Prelaj; Giuseppe Luigi Banna; Luciano Mutti; Yi Hu; Jinliang Wang
Journal:  Transl Lung Cancer Res       Date:  2020-12

2.  The Clinical Significance of Deglycosylated PD-L1 Level Detection Using 28-8 Monoclonal Antibody in Lung Adenocarcinoma.

Authors:  Huiyu Wang; Dingyi Gu; Datian Chen; Jie Mei; Xuejing Yang; Junli Ding; Junying Xu; Meilin Wang; Chaoying Liu; Dong Hua
Journal:  Int J Gen Med       Date:  2022-09-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.